Patent intelligence · US
US 11594345
Method for producing Ac-225 from Ra-226
Method for producing Ac-225 from Ra-226
Patent details — US 11594345
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 28, 2023
- Expiration
- Feb 23, 2043
- Applicant
- Ion Beam Applications
- Claims
- 11
- CPC classes
- A61K, A61K51/00
Quick answer
US 11594345 (Method for producing Ac-225 from Ra-226) is held by Ion Beam Applications. Status: granted. Granted Feb 28, 2023. Expires Feb 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ion Beam Applications
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K51/00
More from Ion Beam Applications
Related pharmaceutical patents in our USPTO index.
-
US 12296053
Nanomaterials comprising triols
granted -
US 12268753
Nanomaterials comprising a biodegradable feature
granted -
US 12133884
Methods of substituting pathogenic amino acids using programmable base editor systems
granted -
US 12059477
Nanomaterials
granted -
US 12016908
Compositions and methods for treating hemoglobinopathies
granted -
US 11795443
Uses of adenosine base editors
granted -
US 11752202
Compositions and methods for treating hemoglobinopathies
granted
Frequently asked questions
What is US patent 11594345?
US 11594345 (Method for producing Ac-225 from Ra-226) is held by Ion Beam Applications. Status: granted. Granted Feb 28, 2023. Expires Feb 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11594345?
Ion Beam Applications is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11594345 expire?
Our index shows an expiration date of Feb 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.